Is Talazoparib included in medical insurance?

Talazoparib (Talazoparib) is used in adults to treat a certain type of breast cancer that has spread to other parts of the body. Talazopanib is also used in combination with other drugs to treat adult patients with prostate cancer that has spread to other parts of the body and when surgery or other treatments to lower testosterone levels have not worked. Usually doctors will determine whether a patient can receive talazopanib treatment based on the type of tumor they have.

Talazopanib is available in capsule form and the recommended dose for the treatment of breast cancer is 1 mg once daily. Treatment should continue as long as the patient continues to benefit from it and the side effects are tolerable. If certain side effects occur, the dose may be reduced or treatment may be interrupted. In a major study involving 431 patients with HER2-negative breast cancer who had BRCA mutations and whose cancer had spread, talazopanib was shown to be effective in extending survival without disease progression. Patients who received talazopanib lived an average of 8.6 months without their disease worsening, compared with an average of 5.6 months for patients who received another cancer drug of their doctor's choice.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).